140 related articles for article (PubMed ID: 37187346)
21. Local relapse of nasopharyngeal cancer and Voxel-based analysis of FMISO uptake using PET with semiconductor detectors.
Nishikawa Y; Yasuda K; Okamoto S; Ito YM; Onimaru R; Shiga T; Tsuchiya K; Watanabe S; Takeuchi W; Kuge Y; Peng H; Tamaki N; Shirato H
Radiat Oncol; 2017 Sep; 12(1):148. PubMed ID: 28877734
[TBL] [Abstract][Full Text] [Related]
22. Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.
O'Halloran PJ; Viel T; Murray DW; Wachsmuth L; Schwegmann K; Wagner S; Kopka K; Jarzabek MA; Dicker P; Hermann S; Faber C; Klasen T; Schäfers M; O'Brien D; Prehn JH; Jacobs AH; Byrne AT
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1673-83. PubMed ID: 26975402
[TBL] [Abstract][Full Text] [Related]
23. Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.
Mair MJ; Ilhan-Mutlu A; Pajenda S; Kiesel B; Wöhrer A; Widhalm G; Dieckmann K; Marosi C; Wagner L; Preusser M; Berghoff AS
Cancer Immunol Immunother; 2021 Dec; 70(12):3643-3650. PubMed ID: 33956203
[TBL] [Abstract][Full Text] [Related]
24. Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.
Iagaru A; Mosci C; Mittra E; Zaharchuk G; Fischbein N; Harsh G; Li G; Nagpal S; Recht L; Gambhir SS
Radiology; 2015 Nov; 277(2):497-506. PubMed ID: 25965900
[TBL] [Abstract][Full Text] [Related]
25. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
[TBL] [Abstract][Full Text] [Related]
26. Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of
Okamoto M; Yamaguchi S; Sawaya R; Echizenya S; Ishi Y; Kaneko S; Motegi H; Toyonaga T; Hirata K; Fujimura M
Biomed Res Int; 2024; 2024():2973407. PubMed ID: 38449509
[TBL] [Abstract][Full Text] [Related]
27. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
28. Diagnosed recurrent glioma and antiangiogenic treatment response by 11C-Methionine PET.
García JR; Baquero M; Bassa P; Soler M; Moragas M; Riera E
Rev Esp Med Nucl Imagen Mol; 2015; 34(6):398-9. PubMed ID: 26092078
[No Abstract] [Full Text] [Related]
29. An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma.
Tanaka T; Tamura R; Takei J; Morimoto Y; Teshigawara A; Yamamoto Y; Imai R; Kuranari Y; Tohmoto K; Hasegawa Y; Akasaki Y; Murayama Y; Miyake K; Sasaki H
J Neurooncol; 2024 Feb; 166(3):557-567. PubMed ID: 38291182
[TBL] [Abstract][Full Text] [Related]
30. [
Provost C; Rozenblum-Beddok L; Nataf V; Merabtene F; Prignon A; Talbot JN
Mol Imaging Biol; 2019 Apr; 21(2):297-305. PubMed ID: 29948641
[TBL] [Abstract][Full Text] [Related]
31. Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas.
Kawai N; Lin W; Cao WD; Ogawa D; Miyake K; Haba R; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1870-8. PubMed ID: 24781871
[TBL] [Abstract][Full Text] [Related]
32. Implications of bevacizumab discontinuation in adults with recurrent glioblastoma.
Anderson MD; Hamza MA; Hess KR; Puduvalli VK
Neuro Oncol; 2014 Jun; 16(6):823-8. PubMed ID: 24596117
[TBL] [Abstract][Full Text] [Related]
33. PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study.
Rogasch J; Beck M; Stromberger C; Hofheinz F; Ghadjar P; Wust P; Budach V; Amthauer H; Tinhofer I; Furth C; Walter-Rittel TC; Zschaeck S
F1000Res; 2020; 9():1350. PubMed ID: 33796277
[No Abstract] [Full Text] [Related]
34. "Paradoxical" findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab.
Yamamoto Y; Tamura R; Tanaka T; Ohara K; Tokuda Y; Miyake K; Takei J; Akasaki Y; Yoshida K; Murayama Y; Sasaki H
Oncotarget; 2017 Nov; 8(61):103890-103899. PubMed ID: 29262608
[TBL] [Abstract][Full Text] [Related]
35. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O.
Bruehlmeier M; Roelcke U; Schubiger PA; Ametamey SM
J Nucl Med; 2004 Nov; 45(11):1851-9. PubMed ID: 15534054
[TBL] [Abstract][Full Text] [Related]
36. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
Levin VA; Chan J; Datta M; Yee JL; Jain RK
J Neurooncol; 2017 Sep; 134(2):325-330. PubMed ID: 28631191
[TBL] [Abstract][Full Text] [Related]
37. The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.
Schaub C; Schäfer N; Mack F; Stuplich M; Kebir S; Niessen M; Tzaridis T; Banat M; Vatter H; Waha A; Herrlinger U; Glas M
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1825-9. PubMed ID: 27318492
[TBL] [Abstract][Full Text] [Related]
38. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
Galldiks N; Dunkl V; Ceccon G; Tscherpel C; Stoffels G; Law I; Henriksen OM; Muhic A; Poulsen HS; Steger J; Bauer EK; Lohmann P; Schmidt M; Shah NJ; Fink GR; Langen KJ
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2377-2386. PubMed ID: 29982845
[TBL] [Abstract][Full Text] [Related]
39. Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma.
Levin VA; Mendelssohn ND; Chan J; Stovall MC; Peak SJ; Yee JL; Hui RL; Chen DM
J Neurooncol; 2015 Mar; 122(1):145-50. PubMed ID: 25575937
[TBL] [Abstract][Full Text] [Related]
40. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.
Pope WB; Xia Q; Paton VE; Das A; Hambleton J; Kim HJ; Huo J; Brown MS; Goldin J; Cloughesy T
Neurology; 2011 Feb; 76(5):432-7. PubMed ID: 21282590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]